Enhanced Treatment and Prevention of Alzheimer's Disease
Legal Citation
Summary of the Inventive Concept
An improved approach to treating and preventing Alzheimer's disease, featuring optimized dosing regimens, enhanced efficacy through combination therapy, and advanced monitoring systems to minimize adverse effects and personalize treatment plans.
Background and Problem Solved
The original patent disclosed a method for treating mild cognitive impairment (MCI) using an aluminum salt. However, the original approach had limitations, including the need for more effective dosing regimens, enhanced efficacy, and improved monitoring systems. The new inventive concept addresses these limitations by introducing optimized dosing regimens, combination therapy with neuroprotective agents, and advanced monitoring systems.
Detailed Description of the Inventive Concept
The new inventive concept comprises four key aspects: 1) optimized dosing regimens, where the pharmaceutical formulation containing an aluminum salt is administered subcutaneously to a patient at a frequency of every 4 weeks for a period of 18 months; 2) enhanced efficacy through combination therapy, where the aluminum salt is administered concurrently with a neuroprotective agent selected from antioxidants, anti-inflammatory agents, and growth factors; 3) advanced monitoring systems, which utilize a computer system to receive and analyze data from a patient's mini-mental state examination (MMSE) scores and generate a personalized treatment plan; and 4) minimization of adverse effects, achieved through monitoring of vital signs and cognitive function at predetermined intervals.
Novelty and Inventive Step
The new claims introduce novel and non-obvious improvements over the original patent, including optimized dosing regimens, combination therapy with neuroprotective agents, and advanced monitoring systems. These innovations provide enhanced efficacy, improved safety, and personalized treatment plans, thereby overcoming the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include varying the frequency or duration of treatment, using different neuroprotective agents or combinations thereof, or incorporating additional monitoring parameters. Variations could also include adapting the treatment approach for different patient populations or disease stages.
Potential Commercial Applications and Market
The enhanced treatment and prevention approach for Alzheimer's disease has significant commercial potential in the pharmaceutical and healthcare industries. The market for Alzheimer's disease treatments is substantial, with an estimated global value of over $10 billion by 2025. The new inventive concept's improved efficacy, safety, and personalized approach position it for strong market adoption and potential leadership in the Alzheimer's disease treatment space.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Neurodegenerative disease treatment, specifically Alzheimer's disease therapeutics, involving pharmaceutical formulations, cognitive assessment, and patient monitoring techniques
Person of Ordinary Skill (PHOSITA) Profile
A medical researcher or pharmaceutical scientist with expertise in neurodegenerative disease treatments, having advanced degrees in pharmacology or neuroscience, familiar with clinical trial methodologies, drug delivery systems, and cognitive assessment protocols
Obviousness Rationale
A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core treatment approach, involving routine optimization of dosing parameters, combination therapy techniques commonly used in neurodegenerative disease management, and standard clinical monitoring practices that would be apparent to a skilled practitioner in the field.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,568 |
|---|---|
| Title | Treatment and prevention of Alzheimer's disease (AD) |
| Assignee(s) | Advantage Therapeutics, Inc. |